marijuana stocks news

OrganiGram Holdings Inc. (OGRMF)

Income Statement Get Income Statement for:
View: Annual Data | Quarterly Data All numbers in thousands
Period Ending Feb 28, 2015 Nov 30, 2014 Jul 31, 2014 Apr 30, 2014
Total Revenue 142   12   –   –  
Cost of Revenue 27 6
Gross Profit 115   6   –   –  
Operating Expenses
Research Development
Selling General and Administrative 539 723 177 24
Non Recurring 2
Others
Total Operating Expenses
Operating Income or Loss (423) (718) (177) (26)
Income from Continuing Operations
Total Other Income/Expenses Net 5
Earnings Before Interest And Taxes (423) (718) (172) (25)
Interest Expense 23
Income Before Tax (446) (718) (172) (25)
Income Tax Expense
Minority Interest
Net Income From Continuing Ops (446) (718) (172) (25)
Non-recurring Events
Discontinued Operations
Extraordinary Items
Effect Of Accounting Changes
Other Items
Net Income (446) (718) (172) (25)
Preferred Stock And Other Adjustments
Net Income Applicable To Common Shares (446) (718) (172) (25)

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Cara Therapeutics, Inc. (CARA) Reports First Quarter 2022 Financial Results

Cara Therapeutics Reports First Quarter 2022 Financial Results Cara Therapeutics, Inc. (Nasdaq:…

Trulieve Cannabis Corp. (TCNNF) Launches New Innovative Product: Refined Crème

Trulieve Launches New Innovative Product: Refined Crème Trulieve Cannabis Corp. (CSE: TRUL)…

Neptune Wellness Solutions Inc. (NEPT) Michael Cammarata’s Resignation Effective February 23, 2024

Neptune Announces Michael Cammarata’s Resignation Effective February 23, 2024 Neptune Wellness Solutions…

AbbVie Inc. (ABBV) Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn’s Disease

AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn’s Disease…